Raymond Capps, MD
Neurology · Murfreesboro, TNNPI 1346444742
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,382 of the $151,823 with a category attached, or 82.6%. 46 manufacturers reported payments, led by AbbVie at 59.0% of the total. Reporting peaked in 2021 at $66,891 and has fallen 99.1% since, to $588 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 937 payments — averaging $162.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$90K
- Biohaven Pharmaceuticals, Inc.$16K
- Lilly USA, LLC$12K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- SK Life Science, Inc.$8K
- Biogen$6K
- plus $12K from 40 others
What the payments were for
- Consulting fees$6,9775%
- Speaking & faculty fees$125,38283%
- Travel & lodging$3,3042%
- Food & beverage$15,94611%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,823 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 67 | $547,289 |
| AustedoDeutetrabenazine | 48 | $370,706 |
| GocovriAmantadine Hcl | 126 | $261,140 |
| NuplazidPimavanserin Tartrate | 48 | $238,685 |
| UbrelvyUbrogepant | 149 | $225,128 |
| Avonex (4 Pack)Interferon Beta-1a | 20 | $213,105 |
| Nurtec OdtRimegepant Sulfate | 94 | $181,985 |
| NourianzIstradefylline | 68 | $164,997 |
| XcopriCenobamate | 96 | $121,995 |
| QuliptaAtogepant | 95 | $116,240 |
| Austedo XrDeutetrabenazine | 11 | $108,266 |
| NeuproRotigotine | 112 | $105,006 |
| Aimovig AutoinjectorErenumab-Aooe | 122 | $99,560 |
| CopaxoneGlatiramer Acetate | 13 | $72,779 |
| RytaryCarbidopa/Levodopa | 107 | $69,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Copaxone | $1,462 | $551,75072 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $642 | $547,28967 claims |
| AbbVieUbrelvy, Qulipta | $89,613 | $341,368244 claims |
| MDD US Operations, LLCGocovri | $566 | $261,140126 claims |
| Acadia Pharmaceuticals IncNuplazid | $234 | $238,68548 claims |
| UCB, Inc.Neupro, Briviact, Vimpat, Nayzilam | $966 | $230,770221 claims |
| BiogenAvonex (4 Pack) | $6,410 | $213,10520 claims |
| PfizerNurtec Odt, Zavzpret | $181 | $201,945112 claims |
| Kyowa Kirin, Inc.Nourianz | $149 | $164,99768 claims |
| SK Life Science, Inc.Xcopri | $7,620 | $121,99596 claims |
| Amneal Pharmaceuticals LLCRytary | $154 | $69,356107 claims |
| Neurelis, Inc.Valtoco | $347 | $52,81749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Murfreesboro
- John SchneiderMurfreesboro$49K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.